.png){kind=icon}
.png){kind=icon}
Return
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
.png){kind=icon}
PRE
AI
DOI：10.1016/j.clml.2025.04.007.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Pooling GRIFFIN and PERSEUS data allowed for more robust analysis of older adults. • Pooled data in patients aged ≥65 years showed a trend in improved PFS with D-VRd versus VRd. • D-VRd also deepened responses and MRD-negativity rates in these older patients. • D-VRd was well tolerated by patients aged ≥65 years, with no new safety concerns.
Keywords:
Minimal residual disease
Older adults
Progression-free survival
Safety
Transplantation
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
2.7
Papers:
427
Citations:
4.2K
Organization
View more organizations